Abstract
Cannabinoids produce a broad array of potential therapeutical effects, including the reduction of nausea in cancer and AIDS patients undergoing chemotherapy [1]. In recent years, two G1 protein-coupled cannabinoid receptors, CB1 and CB2, have been identified and cloned. Whereas the CB2 receptor is preferentially expressed in the central nervous system [2], the CB2 receptor has been described as the predominant form expressed in peripheral immune cells [3]. The discovery of specific cannabinoid receptors was followed by the identification of two endogenous arachidonic acid derivatives, anandamide (N-arachidonylethanolamide) and 2-arachidonylglycerol, which exhibit specific binding affinity to cannabinoid receptors [4, 5]. However, emerging evidence suggests that various cannabinoid actions are mediated via cannabinoid receptor-independent pathways, comprising activation of mitogen-activated protein kinases (MAPKs) [6, 7], alteration of intracellular calcium [8] and cAMP levels [9, 10], inhibition of cytokine expression [11] and induction of histamine release [12].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
McCabe M, Smith FP, MacDonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988; 6:243–246.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TL Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561–564.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61–65.
Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993; 90:7656–7660.
Lee M, Yang KH, Kaminski NE. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 1995; 275:529–536.
Liu J, Gao B, Mirshani F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346:835–840.
Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M, Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 1998; 425:419–425.
Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor-and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 1992; 42:838–845.
Heindel JJ, Keith WB. Specific inhibition of FSH-stimulated cAMP accumulation by Δ9-tetrahydrocannabinol in cultures of rat Sertoli cells. Toxicol Appl Pharmacol 1989; 101:124–134.
Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 1999; 11:691–699.
Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29:58–69.
Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 2001; 1538:252–259.
Shivachar AC, Martin BR, Ellis EF. Anandamide-and Δ9-tetrahydrocannabinolevoked arachidonic acid mobilization and blockade by SRI 41716A [N-(Piperidin-l-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methy1-1H-pyrazole-3-carboximide hydrochloride]. Biochem Pharmacol 1996; 51:669–676.
Reichman M, Nen W, Hokin LE. Δ9-Tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices. Mol Pharmacol 1988; 34:823–828.
Hunter SA, Burstein SH. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 1997; 60:1563–1573.
Bhattacharya SK. Δ9-Tetrahydrocannabinol (THC) increases brain prostaglandins in the rat. Psychopharmacology 1986; 90:499–502.
Hunter SA, Audette CA, Burstein S. Elevation of brain prostaglandin E2 levels in rodents by Δ1-tetrahydrocannabinol. Prost Leukot Essent Fatty Acids 1991; 43:185–190.
Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J Neurosci 1998; 18:5322–5332.
Abadji V, Lin S, Tana G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37:1889–1893.
Hinz B, Brune K, Pahl A. Prostaglandin E2 up-regulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2000; 272:744–748.
Hinz B, Brune K, Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E2 and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000; 278:790–796.
Ellis EF, Moore SF, Willoughby KA. Anandamide and Δ9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 1995; 269:H1859–H1864.
Burstein SH, Hull K, Hunter SA, Shilstone J. Immunization against prostaglandins reduces Δ1-tetrahydrocannabinol-induced catalepsy in mice. Mol Pharmacol 1989; 35:6–9.
Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991; 48:507–515.
Yamaguchi T, Shoyama Y, Watanabe S, Yamamoto T. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. Brain Res 2001; 889:149–154.
Pate DW, Jarvinen K, Urtti A, Jarho P, Fich M, Mahadevan V, Jarvinen T. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci 1996; 58:1849–1860.
Green K, Kearse EC, McIntyre OL. Interaction between Δ9-tetrahydrocannabinol and indomethacin. Ophthalmic Res 2001; 33:217–220.
Hinz B, Brune K. Cyclooxygenase-2-Ten years later. J Pharmacol Exp Ther 2002; 300:367–375.
Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995; 83:493–501.
Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Δ9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436:6–10.
Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997; 272:21181–21186.
Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 2000; 275:33744–33749.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hinz, B., Ramer, R., Brune, K. (2003). Induction of COX-2 Expression by the Endocannabinoid Derivative R(+)-Methanandamide. In: Yazici, Z., Folco, G.C., Drazen, J.M., Nigam, S., Shimizu, T. (eds) Advances in Prostaglandin, Leukotriene, and other Bioactive Lipid Research. Advances in Experimental Medicine and Biology, vol 525. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9194-2_30
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9194-2_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4831-3
Online ISBN: 978-1-4419-9194-2
eBook Packages: Springer Book Archive